Evidence map›Paper›PMID 30955024›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2019

The Mechanism of Bufalin-Induced Apoptosis of K562/A02.

Ying Xie, Xu Yan, Ling Sun

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ying XieDepartment of Blood Transfusion, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Xu YanDepartment of Orthopedics, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
Ling SunDepartment of Hematology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China (mainland).
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND In clinical practice, many patients become multidrug resistant during chemotherapy, resulting in reduced or no healing effect. Therefore, the present study focused on bufalin, which is extracted from a traditional Chinese medicine named Chan Su (Venenum bufonis). We assessed the effect of bufalin in reversing K562/A02 cell drug resistance and inducing apoptosis, and explored the possible mechanism by which bufalin induces K562/A02 cell apoptosis. MATERIAL AND METHODS We used flow cytometry to evaluate intracellular ADM concentration, and RT-PCR and Western blot analysis were used to assess the effect of nuclear factor erythroid-2-related factor 2 (Nrf2) bufalin-related resistance gene expression. We used MTT and flow cytometry to detect apoptosis, and RT-PCR and Western blot were used to detect endoplasmic reticulum stress and apoptosis gene action. RESULTS We found that bufalin can increase the concentration of Adriamycin (ADM) in K562/A02 cells by inhibiting the expression of Nrf2 and related drug resistance factors. The results showed that bufalin induced apoptosis of K562/A02 cells by the IRE1alpha/TRAF2/JNK/caspase-12 pathway. CONCLUSIONS These results suggest bufalin can reverse drug resistance in K562/A02 cells and that it induces apoptosis of K562/A02 cells by the IRE1alpha/TRAF2/JNK/caspase-12 pathway.

Indexed as

ApoptosisBufanolidesChinaDoxorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmHumansK562 CellsMedicine, Chinese TraditionalNF-E2-Related Factor 2RNA, MessengerbufalinBufanolidesDoxorubicinNFE2L2 protein, humanNF-E2-Related Factor 2RNA, Messenger

Identifiers

PMID30955024
PMCPMC6467175
OpenAlexW2927247890

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.